Strategies for Overcoming Drug Interference in Immunogenicity Assessment
Complete the form to view the recording.Share this resource:
Now Streaming On-Demand
Circulating drug can often interfere in the detection of anti-drug antibodies (ADAs). Therefore, it is imperative to develop bioanalytical assays that are able to reliably detect both ADAs as well as neutralizing ADAs (NAbs) in the presence of the drug. This webinar will provide an overview of the different type of interferences as well as the approaches utilized to optimize drug tolerance.
About the Speakers
Lynn Kamen, Ph.D., Scientific Officer, Executive Director, earned her PhD in Immunology at the University of Michigan (MI, USA) and completed a postdoctoral fellowship at the University of California San Francisco (CA, USA). She has spent the past decade working in drug development supporting both large and small molecule formats from early target discovery through clinical development. Most recently, she was a principal scientist at Genentech (CA, USA) where she supported large molecule and novel modality bioanalysis including PK, immunogenicity and biomarker.